$Pfizer(PFE.US) and $LONGBIO-B(01779.HK) both rose slightly, while $Regencell Bioscience(RGC.US) fell slightly—it's all minor moves in the pharma sector. The standout is $Intuitive Surgical(ISRG.US): the stock price has barely moved, but it has been lingering below the 50-day moving average for a while, with a 14-day RSI in the 30s. It's rare for a medtech leader to offer such a prolonged window of weakness.
The penetration logic for surgical robots hasn't changed at all; what's been discounted is the valuation, not the fundamentals. Is this kind of slow bleed in a blue-chip stock the "good company at a discount" scenario from the textbooks?
I personally think it is, but the discipline for left-side accumulation is to build the position in three tranches, don't go all-in at once. The bottom for a blue-chip can grind longer than you think 🤔
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
